EVALUATION OF A NOVEL ORALLY-ACTIVE DIRECT INHIBITOR OF THROMBIN IN ANIMAL-MODELS OF THROMBOSIS

被引：0

作者：

ROTE, WE ^{[1
]}

DEMPSEY, EM ^{[1
]}

OLDESCHULTE, GL ^{[1
]}

ARDECKY, RJ ^{[1
]}

TAMURA, SY ^{[1
]}

NUTT, RF ^{[1
]}

BERGUM, PW ^{[1
]}

TRAN, HS ^{[1
]}

ANDERSON, SM ^{[1
]}

VLASUK, GP ^{[1
]}

机构：

[1] CORVAS INT INC,SAN DIEGO,CA

来源：

CIRCULATION | 1994年 / 90卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：344 / 344

页数：1

共 50 条

[41] A novel orally active inhibitor of HLE
Varga, M
Kapui, Z
Bátori, S
Nagy, LT
Vasvári-Debreczy, L
Mikus, E
Urbán-Szabó, K
Arányi, P
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2003, 38 (04) : 421 - 425
[42] 3-QUINOLINECARBOXAMIDES - A SERIES OF NOVEL ORALLY-ACTIVE ANTIHERPETIC AGENTS
WENTLAND, MP
PERNI, RB
DORFF, PH
BRUNDAGE, RP
CASTALDI, MJ
BAILEY, TR
CARABATEAS, PM
BACON, ER
YOUNG, DC
WOODS, MG
ROSI, D
DROZD, ML
KULLNIG, RK
DUTKO, FJ
JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (11) : 1580 - 1596
[43] Strategies and progress towards the ideal orally active thrombin inhibitor
Renwinkel, JBM
Adang, AEP
CURRENT PHARMACEUTICAL DESIGN, 1999, 5 (12) : 1043 - 1075
[44] Direct Thrombin Inhibitor for LVAD Thrombosis: A Closer Look
Rimsans, Jessica
Sylvester, Katelyn W.
Connors, Jean M.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2017, 23 (05) : 405 - 409
[45] PRECLINICAL EVALUATION OF WR-151327 - AN ORALLY-ACTIVE CHEMOTHERAPY PROTECTOR
GREEN, D
BENSELY, D
SCHEIN, P
CANCER RESEARCH, 1994, 54 (03) : 738 - 741
[46] S 35972, a novel orally active thrombin inhibitor: in vitro and ex vivo anticoagulant activity
Rupin, A.
Mennecier, P.
Vallez, M. O.
Gloanec, P.
De Nanteuil, G.
Verbeuren, T. J.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 447 - 447
[47] In vitro characteristics and antithrombotic effects of LB30870, a potent, orally active and selective direct thrombin inhibitor, in rat model of venous thrombosis.
Park, HD
Kim, TH
Park, JG
Kang, MK
Lee, SG
Kim, IC
Kim, AR
BLOOD, 2001, 98 (11) : 44A - 44A
[48] Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug
Clement, B
Lopian, K
DRUG METABOLISM AND DISPOSITION, 2003, 31 (05) : 645 - 651
[49] VALIDITY OF ANIMAL-MODELS OF THROMBOSIS - VARIATION IN THE PATHOPHYSIOLOGIC ACTIVATION PROCESSES
KUMAR, A
WILLIAMSON, K
FAREED, J
FEDERATION PROCEEDINGS, 1986, 45 (04) : 966 - 966
[50] Synthesis and pharmacological evaluation of a novel orally active factor Xa inhibitor
Nishida, H
Ohkouchi, M
Mukaihira, T
Saitoh, F
Nakamura, Y
Miyazaki, Y
Satoh, T
Mizuno, M
Kamino, T
Hosaka, Y
Shinozaki, M
Oono, T
Muramatsu, H
Shiromizu, I
Matsusue, T
Kamiya, M
Miyauchi, M
Yokoyama, T
Kakinuma, C
Ogihara, T
Yanagibashi, K
Isomura, Y
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2660 - U2661

← 1 2 3 4 5 →